Tennessee is currently home to 1928 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
01/26/2024
Locations: Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers, Nashville, Tennessee
Conditions: Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Gastro One - Germantown Office - Wolf Park Drive, Germantown, Tennessee
Conditions: NASH - Nonalcoholic Steatohepatitis
Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
Recruiting
The purpose of this research study is to examine the effect of cardiac sympathetic denervation (CSD) surgery on life threatening abnormal heart rhythms called ventricular tachycardia or ventricular fibrillation that can lead to sudden cardiac death. Subjects will be asked to participate in this research study if they have recurrent ventricular tachycardia (at least one ICD shock for ventricular tachycardia) and have undergone at least one catheter ablation procedure or have ventricular tachycard... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Sudden Cardiac Death, Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy
Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)
Recruiting
A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease (DED)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Total Eye Care, PA, Memphis, Tennessee
Conditions: Dry Eye Disease
Combined Electric and Acoustic Hearing (EAS) in Children and Adults
Recruiting
Cochlear implants are surgically implanted devices which restore the ability to hear to the hearing impaired. Improvements in surgery and electrodes have results in an increased number of adults and children who have residual hearing and can benefit from electric and acoustic hearing in the same ear. This is called Electric Acoustic Stimulation (EAS). Many studies have shown that adult EAS users show significant benefits for speech understanding in noise and spatial hearing tasks as compared to... Read More
Gender:
All
Ages:
5 years and above
Trial Updated:
01/16/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Cochlear Implant, Hearing Loss
Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency
Recruiting
The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Southeastern Dermatology, Knoxville, Tennessee
Conditions: Hyperhidrosis Primary Focal Axilla
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Recruiting
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify... Read More
Gender:
All
Ages:
Between 15 years and 80 years
Trial Updated:
01/10/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
C-Brace Prospective Registry
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
All
Ages:
All
Trial Updated:
01/09/2024
Locations: Excel P&O, Kingsport, Tennessee
Conditions: Pareses, Lower Extremity
Time to Move in Pregnancy Hyperglycemia
Recruiting
This randomized controlled crossover trial of 36 pregnant individuals with gestational diabetes (GDM) or gestational glucose intolerance (GGI) will: Determine the effects of physical activity (PA) timing, specifically 30 minutes of moderate intensity walking or stepping in the morning (between 5am-9am, within 30-40 minutes of starting breakfast), versus late afternoon/evening (between 4pm-8pm, within 30-40 minutes of dinner) on glucose across the 24-hour cycle. Explore the potential effects of... Read More
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
01/08/2024
Locations: The University of Tennessee Medical Center, Knoxville, Tennessee
Conditions: GDM, Physical Activity, Hyperglycemia, Glucose Intolerance, Circadian Rhythm, Exercise
Use of Hand-held Dynamometry to Obtain Objective Measures of Lower Extremity Force Production With Chronic Stroke
Recruiting
This study wants to know if using handheld dynamometry (HHD) to test leg strength in persons who have had a stroke, will reduce mistakes and give therapists better information to use for therapy. This study will collect normal values of leg muscle peak force production, cumulative peak force production, and sustained peak force production in patients with chronic stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/06/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Chronic Stroke, Weakness, Muscle
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Recruiting
This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize C... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Baptist Cancer Center, Memphis, Tennessee
Conditions: Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Recruiting
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors